Edwards Beat Analysts' And Its Own Projections in Q2 As TAVR Volumes Recover
The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.
You may also be interested in...
The company’s third-quarter sales were up 4% year-over-year as transcatheter aortic valve replacement procedure volumes returned to pre-pandemic levels.
Sapien 3 is now indicated to treat failed right ventricular outflow tract conduits, surgical bioprosthetic pulmonary valves and transcatheter aortic valves.
The company is sponsoring an early feasibility trial of the Intrepid transcatheter valve replacement system for patients with severe tricuspid regurgitation.